FY22-DBH- Naloxone HCL 4MG Nasal Spray

The District of Columbia Department of Behavioral Health (DBH) is seeking to procure Naloxone HCL 4MG Nasal Spray through a competitive procurement process for fiscal year 2022. The contract opportunity focuses on acquiring a critical overdose reversal medication to support public health initiatives addressing opioid-related emergencies. Potential vendors must provide high-quality, FDA-approved nasal spray units that can rapidly counteract opioid overdose symptoms. The solicitation requires vendors to demonstrate compliance with pharmaceutical distribution regulations, provide detailed product specifications, and ensure reliable supply chain management. The procurement follows a standard competitive bidding process with a posted date of March 10, 2022, and a firm submission deadline of March 25, 2022, providing vendors approximately two weeks to prepare and submit comprehensive proposals. Interested bidders should carefully review all technical specifications, packaging requirements, and delivery expectations outlined in the full solicitation documents.

The contract opportunity does not explicitly indicate specific set-aside designations or small business preferences in the provided information. However, typical District of Columbia procurement practices often include opportunities for local, minority-owned, and disadvantaged business enterprises. The procurement appears focused on pharmaceutical suppliers with established capabilities in medical supply distribution, particularly those with experience providing emergency medical intervention products. While specific budget ranges are not disclosed in the available information, naloxone procurement contracts typically range from tens of thousands to several hundred thousand dollars depending on anticipated usage and distribution requirements. Vendors will likely need to demonstrate substantial manufacturing capacity, quality control processes, FDA compliance, and the ability to meet rapid deployment timelines for this critical public health intervention. Potential respondents should be prepared to provide comprehensive documentation of their manufacturing capabilities, product certifications, and delivery logistics.